People with Huntington’s disease are more likely to take Austedo (deutetrabenazine) as directed, compared with the similar medication…
Articles by Marisa Wexler, MS
The experimental oral medication branaplam (LMI070) has been granted fast track designation by the U.S. Food and Drug Administration (FDA)…
AMT-130, an investigational gene therapy for the treatment of Huntington’s disease, was overall well-tolerated up to a year…
Treatment with valbenazine significantly lessened chorea — a motor symptom characterized by jerky, unpredictable, and involuntary movements — in…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to SAGE-718 as a potential therapy for…
Huntington’s disease patients who have not yet developed symptoms have a different relationship with time than otherwise-healthy individuals, according…
Brain cells called glia work to protect the brain from damage in Huntington’s disease by reducing the expression of…
People with Huntington’s disease who have had more formal education tend to be diagnosed earlier and have milder symptoms…
Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for…
Treatment with tominersen failed to show evidence of clinical benefit in adults with Huntington’s disease during the Phase 3…